In addition, factors such as HER2 heterogeneity, loss of HER2-positive status, acquired HER2 mutations, HER2 heterodimerization, altered intracellular signaling, and the tumor immune microenvironment all contribute to HER2 drug resistance [14, 20]. The gene discussed is ERBB2; the disease is neoplasm.